Treating status migrainosus in the emergency setting: what is the best strategy? by Vécsei, László et al.
Treating status migrainosus in the emergency setting: what is the best strategy? 
László Vécsei1,2*, Délia Szok1, Aliz Nyári1, János Tajti1 
1Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, 
University of Szeged, Semmelweis u. 6, H-6725, Szeged, Hungary 
2MTA-SZTE Neuroscience Research Group, Semmelweis u. 6, H-6725, Szeged, Hungary 
*Corresponding author:  
László Vécsei 
E-mail: vecsei.laszlo@med.u-szeged.hu 
Tel.: +3662545348 
FAX: +3662545597 
 
Abstract 
 
Introduction: Migraine is a disabling primary headache disorder with unknown exact 
pathomechanism. Status migrainosus is a complication of migraine (with or without aura), 
representing an attack that lasts for more than 72 hours. There is a paucity of data published 
with regards to its pathomechanism and therapeutic options. 
Areas covered: The authors review the literature on status migrainosus from PubMed 
published between 1999 and January 2018. The authors specifically look at the therapeutic 
possibilities of status migrainosus in the emergency department in patients that have and have 
not already been treated with serotonergic agents, the other one has not. Additional discussion 
is given to the rare complications of migraine. 
Expert opinion: Status migrainosus is a devastating condition; therefore, the primary goal is 
to prevent its development with proper acute and prophylactic migraine medication. If this 
treatment fails, the patient should be treated in the emergency setting. Due to the severity of 
the condition, parenteral pharmacotherapy is recommended. However, high-quality 
randomized trials are lacking. The currently available data suggests the use of intravenous 
fluids, corticosteroids, magnesium sulfate, anticonvulsive drugs, nonsteroidal anti-
inflammatory drugs, antiemetics, and serotonergic agents for the treatment of status 
migrainosus. Still, there is a need for personalized and causal therapy for migraine sufferers. 
 
 Keywords: anticonvulsive drugs, antiemetics, corticosteroids, emergency, intravenous 
hydration, magnesium sulfate, migraine, nonsteroidal anti-inflammatory drugs, serotonergic 
agents, status migrainosus, treatment. 
1. Introduction 
Migraine is a common neurovascular primary headache disorder, which is ranked among the 
ten most disabling conditions worldwide [1]. It has high socio-economic and personal impacts, 
disrupting the quality of life of the patients [2-6]. According to the International Classification 
of Headache Disorders, 3rd edition (ICHD-3), migraine is divided into episodic (with or 
without aura) and chronic forms [7]. Clinical signs of a migraine attack are characterized by 
unilateral location, pulsating quality, moderate or severe intensity, aggravation by routine 
physical activity, and association with nausea and/or vomiting, photophobia, and phonophobia 
[7]. 
The most severe manifestation of the disease is status migrainosus (SM), which is considered 
to be a subclass of migraine-related complications according to ICHD-3 [7]. SM equally 
appears in both main subcategories of migraine, i.e. migraine with and without aura [7]. By 
definition, SM is a debilitating migraine attack that lasts for more than 72 h and associates 
with devastating accompanying symptoms (e.g. nausea and vomiting). The essence of the 
diagnostic criteria is the following: SM can occur both in patients of migraine with or without 
aura and it is typical of previous attacks except for the duration and severity of the attack. SM 
is often a consequence of medication overuse headache or the malpractice of acute treatment 
of migraine attacks [8]. The definition of medication overuse headache is based on the acute 
or prophylactic medication-associated headache, which occurs 15 or more days per month for 
three or more consecutive months [7]. 
The definition of refractory or intractable migraine is still under debate, with several 
proposals having been made by different headache specialists. A comprehensive definition of 
refractory headache is the failure of different acute and preventive medications [9]. 
Migraineurs who belong to this category are candidates for developing medication overuse, 
chronic migraine, and, finally, even SM. These patients are victims of the ‘just world 
hypothesis’ [10]. Patients with migraine with aura can develop complications. When the aura 
symptoms persist for more than one week, it is called ‘persistent aura without evidence of 
infarction on neuroimaging’. If the aura lasts more than one hour and less than one week, it is 
referred to as ‘prolonged aura’. The next subtype of complications of migraine is ‘migraine 
aura status’, with a diagnostic criterion of at least three auras occurring over a period of 3 
days [7]. These types of complications of migraine requires special intention and aggressive 
treatment in the emergency department (ED) setting.  
 
2. Epidemiology 
Among the different disorders in the ED setting, headache is the fourth most frequent 
diagnosis in the United States [11]. The relative frequency of ED visits due to headache is 
over 4% [12]. Migraine, in particular, is likewise a very frequent disease in the ED setting. 
Indeed, some one-third of the 5 million headache ED visits annually in the USA is due to 
migraine [13-15]. A French 11-year retrospective analysis revealed that 24 of 8821 
migraineurs had SM, 3 of them had migraine aura status, and 1 had both types [16]. An 
interesting finding is that the frequency of migraine attacks before or after SM is independent 
of the process of SM, and the relapse rate of SM is high [16]. Migraine-related health 
condition is quite expensive. The estimated annual healthcare costs for migraine regarding ED 
visits were 700 million USD in the USA [14], [17]. 
 
3. Therapeutic options of treating SM in the ED setting 
Good clinical practice is based on the knowledge gathered along the principles of evidence-
based medicine. When preparing the present review, we analyzed data related to this topic 
from PubMed records published between 1999 and January 2018. The literature search was 
conducted with the key words ‘status migrainosus’, ‘emergency’, and ‘therapy’ or ‘treatment’ 
or ‘management’. All authors contributed to the conduction of the literature review. Only 
abstracts published in English language were considered. Surprisingly, only very few 
randomized controlled trials are available concerning SM; therefore, our review incorporates 
every single report meeting the above criteria. 
Triptans and dihydroergotamine (DHE) represent the gold standard for acute migraine 
medication. If the patient already received one of these serotonergic agents within the first 72 
hours and the severe headache still present (i.e. SM), the following pharmacons can be 
recommended in the ED setting: parenteral hydration (intravenous (IV) fluids), corticosteroids 
(e.g. IV dexamethasone (DM)), IV magnesium sulfate, anticonvulsive drugs (e.g. IV 
valproates or IV levetiracetam (LEV)), IV antiemetics/antidopaminergics (e.g. IV 
metoclopramide, IV prochlorperazine or IV haloperidol), and nonsteroidal anti-inflammatory 
drugs (NSAIDs; IV ketorolac) and  IV acetaminophen). On the other hand, if the migraineur 
did not receive DHE or triptans, rapid-action parenteral (subcutaneous (SC), nasal spray, 
intramuscular (IM), sublingual, or rectal) triptans or DHE (IV, IM, SC, intranasal, or 
pulmonary inhaler) should be used for treatment [18]. Attention should be paid to 
contraindications, safety profile (adverse events and severe adverse events), and tolerability of 
the above drugs. Moreover, patient comorbidities should also be taken into account. 
 
3.1. Therapeutic options of migraineurs who were treated with serotonergic 
agents (triptans and DHE) but were unresponsive within a 72-h long period 
 
3.1.1. IV fluid hydration 
The majority of SM patients are dehydrated due to excessive and prolonged vomiting. Some 
30% of patients suffering from nausea are unable to take oral medications, whereas this rate is 
42% in those who vomit [19]. Therefore, IV hydration (e.g. with physiological saline) is 
necessary for these patients [12]. The recommended dosage is 500-1000 ml, maximum 2000-
3000 ml [20]. There is a debate about the pain-reducing effect of IV fluid therapy. 
Surprisingly, IV fluid administration may reduce the headache intensity in SM patients and 
improves their comfort [20]. However, there is at present insufficient evidence to conclude on 
whether IV fluid hydration per se can indeed decrease the pain severity in SM patients in the 
ED setting [21,22]. Regarding safety profile, in the case of excessive IV fluid administration, 
the monitorization of the cardiopulmonary status is required. 
 
3.1.2. Corticosteroids 
The first written memory about the use of the steroids for treating severe migraine attacks 
dates back to as early as 1967 [8,23]. The idea is based on neurogenic inflammation, which is 
a potential component of the pathogenesis of a migraine attack. During neurogenic 
inflammation, intracranial blood vessels are dilated and plasma protein extravasation and 
neuropeptide (e.g. calcitonin gene-related peptide (CGRP), pituitary adenylate cyclase-
activating polypeptide (PACAP)) release from the dural sensory nerve endings occur, which 
play crucial roles in the activation of the trigeminovascular system via peripheral and central 
sensitization [24-31]. Steroids may mitigate this neurogenic inflammation [15]. 
The most commonly used systemic glucocorticoids are hydrocortisone, prednisolone, 
methylprednisolone, and DM. Among them, parenteral DM is the most commonly used 
therapy in migraine [32]. 
Concerning the safety issue, corticosteroids can be administered up to six times annually 
[32,33]. However, the role of corticosteroids in the management of acute migraine is ill-
defined. The efficacy of steroids in the treatment of SM is debated. 
 
3.1.2.1. Dexamethasone 
DM is a synthetic pregnane corticosteroid drug and derivative of cortisol (hydrocortisone) 
with an anti-inflammatory potency six times higher than that of prednisone, acting as an 
agonist of the glucocorticoid receptor (Figure 1a). As regards its pharmacokinetic profile, the 
bioavailability is 80–90% and protein binding is 77%. The molecule is metabolized by liver 
and excreted by urine (65%) [34]. Its biological half-life is long (36-72 h) [8]. 
The optimal dose of IV DM in the treatment of acute migraine is unclear, the range is between 
10 and 24 mg [32,35]. The Canadian Association of The Emergency Physicians reported in 
1999 that DM may be of benefit for patients with status migrainosus (Grade B – some 
evidence, but the evidence is suboptimal) [14,36]. The American Headache Society provided 
an evidence-based treatment recommendation for adults with acute migraine in the ED, in 
which parenteral DM reached level B (should be offered) for the prevention of migraine 
recurrence [35]. 
A randomized double-blind placebo-controlled multicenter trial revealed that 10 mg of IV 
DM might be useful for SM patients [15]. An article which contains a 65-year systematic 
review with pooled analysis revealed that corticosteroids have a favorable effect in SM [33]. 
The Agency for Healthcare Research and Quality recommended corticosteroids only as an 
ultimate choice for SM therapy, whereas the Canadian guidelines suggested DM as a fourth-
line treatment for drug-refractory migraine [33,37,38]. A meta-analysis of randomized 
controlled trials for preventing the recurrence of severe migraine attacks revealed that IV DM 
was more effective than placebo [39]. Concerning the safety profile of DM, the most frequent 
adverse events include drowsiness, dizziness, nausea, and vomiting in the ED [15,35]. A 
typical treatment-related adverse event of DM is the loss of glycemic control in diabetic 
patients [15,35]. Caution should be taken of an irreversible adverse event of DM, i.e. 
avascular necrosis [35]. The contraindications are as follows: active peptic ulcer disease, 
uncontrolled hypertension or infections, and immunosuppression [40] (Table 1.). 
 
3.1.3. Magnesium sulfate 
Magnesium ion as an intracellular cation is a cofactor for numerous processes, such as energy 
production and excitability. The initiation and propagation of the migraine aura is related to 
the mechanism of cortical spreading depression (CSD), which is a slowly propagating 
depolarization wave of neuronal and glial cells in the brain [41-43]. Magnesium, as an N-
methyl-D-aspartate (NMDA) receptor antagonist, can influence the glutamate-related 
mechanisms of CSD and thereby the trigeminovascular activation, i.e. the generation of a 
migraine attack [41,42]. In the everyday practice in an ED setting, parenteral (IV) magnesium 
sulfate is widely available and used (Figure 1b). The dose of magnesium sulfate therapy for 
SM is 500-1000 mg IV in the ED setting. Magnesium sulfate may be one of the options for 
treating SM [20,44]. In a randomized study, magnesium sulfate showed beneficial and fast-
acting effect in the alleviation of acute migraine [37,45]. On the contrary, a meta-analysis 
revealed no benefit of IV magnesium sulfate for acute migraine [46]. Reported adverse events 
of magnesium sulfate in the case of IV administration include flushing and hypotension 
[20,35]. The contraindication is hypermagnesemia. Notably, magnesium sulfate can be used 
safely during pregnancy [47]. 
 
3.1.4. Anticonvulsive drugs 
One of the comorbid conditions of migraine is epilepsy. The theoretical basis of a common 
therapy is the shared pathomechanism, such as CSD/depolarization, the altered balance of 
excitatory glutamate and inhibitory gamma-aminobutyric acid (GABA)-mediated 
transmission, and the pathological activation of voltage-gated ion channels (e.g. N-type, L-
type, and P/Q-type calcium-ion channels, and sodium ion channels) [48]. 
 
3.1.4.1. Valproates (valproic acid and sodium valproate) 
The effect of valproates in the alleviation of migraine pain is still debated [49]. Valproates 
probably act via inhibiting GABA transaminase and as sodium ion channel blockers [50]. 
Experimental studies revealed that valproates influenced the trigeminovascular system 
(diminished the serotonergic neuronal activation of the dorsal raphe nucleus), the nociceptive 
transmission, and the cortical hyperexcitability through the GABA-A receptor [50-52]. 
As regards the pharmacokinetic parameters of valproic acid, it is strongly bound to plasma 
protein, metabolized by cytochrome P450 enzymes, and excreted into the urine [49] (Figure 
1c). Based on the results of a randomized open-label study, sodium valproate IV (500-1000 
mg) demonstrated beneficial effect in the treatment of prolonged migraine without aura (i.e. 
when the pain began more than 4 h but less than 72 h ago) [52]. The possible adverse events 
of a single dose of IV sodium valproate are not meaningful [20,35]. One should be cautious 
with IV sodium valproate therapy in case the patient is on oral topiramate therapy for 
migraine prevention because hyperammonemia with encephalopathy can occur [53,54]. Based 
on the latest statement of the European Medicines Agency, valproate should not be used in 
pregnancy (http://www.ema.europa.eu/ema/). An additional contraindication is liver disease 
[12]. 
 
3.1.4.2. Levetiracetam 
LEV, a second-generation anticonvulsive drug widely used in epileptic patients, may be of 
benefit in SM, based on a single case report [55]. LEV has several modes of action, including 
GABAergic and glycinergic mechanisms, and it uniquely binds to synaptic vesicle protein 2A 
[55]. In a preclinical trigeminal pain model, LEV demonstrated antinociceptive effects [56]. 
(Figure 1d) The administered dosage was 1000 mg of IV LEV over 15 min in a female 
patient with epilepsy and migraine with aura, and the outcome was favorable. No adverse 
event occurred [55]. 
 
3.1.5. NSAIDs and acetaminophen 
Among the most widely used NSAIDs applied as analgesics for the relief of headache, only 
IV ketorolac, and also IV acetaminophen are recommended as first-line treatment for acute 
migraine in the ED setting (Figure 1e and 1f) [12,20,35,57]. The mode of action of NSAIDs 
as cyclooxygenase enzyme inhibitors in migraine is based on their influence on the activation 
of the trigeminovascular system [58]. The recommended dosage of IV ketorolac is 30 mg, 
whereas that of IV acetaminophen is 1000 mg [20,35]. Regarding the safety profile of 
acetaminophen, the central nervous system-related adverse events include hyperacusis and 
photophobia, whereas the gastrointestinal-related adverse events are nausea and liver toxicity 
[58]. Common adverse events of ketorolac include nausea and drowsiness [59]. 
Gastrointestinal hemorrhage and hepatic dysfunction are the contraindications for the 
administration of ketorolac and acetaminophen, respectively. 
 
3.1.6. Antiemetics/Antidopaminergic drugs 
Among the most common associated symptoms, nausea occurred in more than 90%, whereas 
vomiting in about 70% of all migraineurs [19]. In the ED setting, the following IV antiemetics 
are recommended as a first-line therapy for nauseated and vomiting migraineurs: IV 
metoclopramide, IV prochlorperazine, or IV haloperidol (Figure 1g, h, i)[12,20,35,57]. 
The mode of action of these drugs is dopamine-receptor antagonism. The recommended IV 
dosage is 10 mg for metoclopramide, 10 mg for prochlorperazine, and 2-5 mg for haloperidol. 
Adverse events of these drugs include extrapyramidal symptoms, such as akathisia, tardive 
dyskinesia, motor agitation, pseudoparkinsonism, and drowsiness [20,60]. The 
contraindication for the administration of IV prochlorperazine is prolonged QT interval; 
therefore, prior ECG is recommended [20]. 
 
3.2. Therapeutic options of migraine patients who were not treated with 
serotonergic agents but only with oral NSAIDs and acetaminophen, and oral 
antiemetics during within a 72-h long period 
 
3.2.1. Serotonergic agents 
Historically, serotonergic (5-hydroxytryptamine, 5-HT) system has long been implicated in 
the pathogenesis of migraine attack. The first observation was the finding of the Sicuteri 
group in the early 1960s that 5-hydroxyindoleacetic acid (5-HIAA, the breakdown product of 
5-HT) was increased in the urine during migraine attack (this article can be found in the file of 
the Int Arch Allergy 1961;19:55–58). In the pioneering years, DHE was recommended for 
severe migraine headache, whereas later Humphrey and his group developed 5-HT1B/1D 
receptor agonists called triptans, the use of which is still the gold standard first-line treatment 
for an acute migraine attack [61]. 
 
3.2.1.1. DHE 
As regards the strength of supporting evidence, the effectivity of DHE nasal spray and oral 
inhaler have level A, whereas that of DHE administered IV, IM, or SC have level B evidence 
for the treatment of acute migraine, prolonged migraine, and SM (Figure 2a) [57,62]. In the 
ED setting, SC and IV routes (1 mg of DHE) are recommended [35]. The safety profile 
depends on the route of administration. Mild nausea is a possible adverse event of IV DHE 
administration, whereas nasal congestion and throat irritation frequently occur during 
intranasal application [63]. Contraindications of DHE are similar to those of triptans, 
predominantly including cardiovascular diseases and pregnancy [58,62,64]. 
 
3.2.1.2. Triptans 
The possible routes of administration of triptans is numerous, including oral, SC, nasal spray, 
patch, transdermal iontophoresis, and rectal routes. In the ED setting, among parenteral 
formulations, the SC route is recommended as first choice regarding the way of application of 
triptans. Before administration of triptans, ECG should be performed to look for ischemic 
signs [20]. In a severe and long-lasting or recurrent migraine headache, SC sumatriptan (6 
mg) should be offered (level B) (Figure 2b) [35]. Common adverse events of SC sumatriptan 
application are chest tightness, rash at injection site, generalized weakness, and dizziness [35]. 
Contraindications of triptans are cardiovascular diseases, uncontrolled hypertension, and 
pregnancy [12]. 
 3.3. Therapeutic options for rare manifestations of migraine  
 
3.3.1. Migraine with prolonged aura 
The clinical picture of prolonged aura include one or more fully-reversible aura symptoms, 
such as visual, sensory, speech- and/or language-related, motor, brainstem, and retinal 
complaints [65]. In the ED setting, migrainous infarction should be excluded by brain MRI in 
these patients [20]. There are several therapeutic options available; however, only intranasal 
ketamine has so far been investigated in a randomized double-blind controlled trial. 
Intranasally applied ketamine in 25 mg dosage significantly reduced the severity but not the 
duration of aura [66]. Other treatment possibilities include triptans, IV magnesium sulfate 
with IV prochlorperazine, IV verapamil, oral acetazolamide, IV furosemide, IV divalproex 
sodium (sodium valproate plus valproic acid), and IV methylprednisolone [20,65]. In drug-
resistant cases, one of the possibilities is the greater occipital nerve block with an anesthetic 
agent, which may be an effective symptomatic treatment [67]. 
 
3.3.2. Persistent aura without infarction 
The typical age of onset is around 30 years (ranging between 7 and 74 years), with a female 
predominance [68]. Numerous medications are mentioned in the literature; however, only few 
showed efficacy, which include antiepileptics (divalproex sodium and lamotrigine), calcium 
ion channel antagonist (nimodipine), diuretic (furosemide), selective serotonin reuptake 
inhibitor (sertraline), and others (e.g. acetylsalicylic acid and baclofen) [68].  
 
3.3.3. Migraine aura status 
This subtype of complications of migraine with aura is a rare but disabling condition, which 
usually presents with visual symptoms and in elderly patients [69,70]. Due to its rarity, only 
few therapeutic data have so far been reported in the literature. The successful medications 
reported include lamotrigine, acetazolamide, folic acid, acetylsalicylic acid, and 
cyproheptadine [69]. 
 
3.3.4. Ictal epileptic headache 
In the past decade, the term ‘ictal epileptic headache’ has been increasingly used in the 
literature [71, 72]. Eventually, the latest IHS classification created a new subclass under 
heading ‘7. Headache attributed to non-vascular intracranial disorder’, with the subheading 
‘7.6. Headache attributed to epileptic seizure’ [7]. The diagnostic criteria of ictal epileptic 
headache are as follows: ‘headache caused by and occurring during a partial epileptic seizure, 
ipsilateral to the epileptic discharge, and remitting immediately or soon after the seizure has 
terminated’ [7]. Of note, several reports have described cases with non-convulsive status 
epilepticus (predominantly with occipital epileptic focus) that mimicked status migrainosus 
[72, 73]. For the treatment of this rare painful non-convulsive seizure type, anticonvulsant 
drugs (e.g, IV benzodiazepines or IV phenytoin) should be used [72, 73]. 
 
4. Conclusion 
SM is a rare but highly disabling complication of migraine. The management of these 
severely ill patients should be carried out in the ED setting and requires pharmacotherapy. 
The majority of the recommended pharmacons has not been subjected to randomized clinical 
trials and were administered only to a small number of migraineurs even if tested in such a 
setting. Therefore, the treatment of such cases represents a big challenge for ED doctors and 
headache specialists. 
At present, the available drugs for treating SM in the ED setting include: IV fluids 
(physiological saline), corticosteroids (IV dexamethasone), IV magnesium sulfate, 
anticonvulsive drugs (IV valproates, IV levetiracetam), IV ketorolac, IV acetaminophen, IV 
antiemetics (metoclopramide, prochlorperazine, haloperidol), and serotonergic agents 
(dihydroergotamine, sumatriptan). The route of administration of these drugs is also important, 
as it generally means parenteral application. It is necessary to reveal the exact 
pathomechanism of SM and to develop novel drugs in the near future, which are to be 
evaluated in rigorously designed clinical trials. 
 
5. Expert opinion 
The effective treatment of acute migraine attacks is a shared task of family doctors, 
neurologists, and headache specialists. In the case of a therapeutic failure, migraine patients 
have a high chance to develop SM and to be admitted to the ED. Before starting to treat SM, 
the definite diagnosis should be established. Symptomatic headaches e.g. those caused by 
venous sinus thrombosis, intra/extracranial arterial thrombosis with cerebral 
microembolisation, primary or metastatic brain tumors, brain abscess, or meningoencephalitis 
must be excluded with proper neuroimaging methods (e.g. magnetic resonance imaging and 
magnetic resonance angiography).  
The difficulties of effective therapy stem from the unclear exact pathomechanism and genetic 
background of migraine. One of the leading hypotheses of the pathogenesis of the initiation 
and maintenance of a migraine attack emphasizes the activation and sensitization of the 
trigeminovascular system via the involvement of different neuropeptides. Currently, a few 
specific (such as serotonergic agents (i.e. DHE and triptans)) and non-specific (such as 
NSAIDs and antiemetics) acute anti-migraine drugs are available. The weakness of this 
therapeutic regime is that they are not effective in every single attack and migraineur. Even 
more, the available medications may have adverse events, which can result in intolerability 
and loss of patient adherence. Concomitant diseases can contraindicate the use of these 
pharmacons. These unfavorable conditions can lead to the admission of these seriously ill 
migraineurs to the ED. 
The goal of the ED medical staff responsible for the care of SM patients is the rapid relief of 
the headache and concomitant clinical signs. The ED specialists also face the problem that the 
pathomechanism of SM is largely unknown and, therefore, causal pharmacotherapy is 
unavailable. The majority of medications used has not been evaluated in randomized 
multicenter double-blind clinical trials. Despite this, on the basis of clinical experience, the 
following drugs are recommended: IV fluids, IV corticosteroids, IV magnesium sulfate, IV 
anticonvulsive drugs, IV ketorolac, IV acetaminophen, IV antiemetics, and IV and SC 
serotonergic agents. Our view about the indication of the treatment in the ED setting is based 
on what type of medication (serotonergic agents and/or NSAIDs) was used first, after the 
onset of the migraine attack. In the case of a medication overuse headache, we strongly 
recommend to start detoxification in the ED setting. 
 
Brief overview of the recommended treatments 
IV fluid hydration for SM patients in the ED setting is world-wide available and cost-effective 
if the migraineur is severely dehydrated due to long-lasting and excessive vomiting. In 
addition, IV fluids can prevent antiemetic-induced hypotension, which are frequently used 
and are recommended as first-line drugs for the treatment of SM. 
Among corticosteroids, IV DM was evaluated in clinical trials. The long half-life of DM is a 
favorable property from the aspect of SM treatment. DM is globally available and inexpensive. 
We point out that IV administration of DM is the most beneficial due to its linear 
pharmacokinetics [34]. The clinical efficacy of DM strongly depends on its pharmacokinetic 
and pharmacodynamic features. Smoking does not affect the pharmacokinetics of DM. In the 
daily practice, it is necessary for the clinician to be aware of the possible treatment-related 
adverse effects of DM; however, the occurrence of irreversible adverse events is low; 
therefore, the physicians should not withheld the use of DM in the ED setting. DM is on the 
List of Essential Medicines of the World Health Organization (WHO), as one the most 
effective and safe medicines in a healthcare system. 
Magnesium sulfate is also widely available, it does not associate with serious adverse events 
and can be given also to pregnant migraineurs. In acute migraine treatment, the effectiveness 
of IV magnesium sulfate is, however, debated. It may have some effect in the treatment of SM, 
and thus we recommend this drug as a possible therapeutic option; however, its evidence is 
far from overwhelming. 
Until now, the few data assessing the effectivity of anticonvulsants (valproates and 
levetiracetam) in the treatment of SM showed beneficial effects; however, large randomized 
clinical studies are needed in near future to draw firm conclusions. 
We emphasize that in the ED setting, SM patients should be treated only with IV ketorolac 
among NSAIDs or IV acetaminophen. 
Antiemetics as dopamine receptor antagonists have antihistamine and anticholinergic effects 
as well; therefore, they can cause sedation as an adverse event, which can be beneficial for 
SM patients. Furthermore, they improve gastric motility and intestinal absorption, which are 
important for the rapid onset of effect of other used drugs. 
In our opinion, DHE can be useful in the treatment of SM with broad spectrum of routes of 
administration. 
Surprisingly, the use of triptans for treating severe migraine or SM in the ED setting is very 
rare, only between 3-5% [14]. On the contrary, the application of opioids is very common 
(48-60%) [14]. Injectable morphine and hydromorphone are strongly recommended to be 
avoided in the therapy of SM in an ED setting [35]. Therefore, we promote the more frequent 
use of triptans, taking into account its safety and tolerability issues, however [58]. 
As an ultimate possibility, if the above mentioned medications failed to provide relief, the 
greater occipital nerve block may be helpful [20,67,74]. 
 
Rare manifestations of migraine, such as migraine with prolonged aura, persistent aura 
without infarction, and migraine aura status, together with ictal epileptic headache represent 
diagnostic and therapeutic challenges in the clinical practice, especially in the ED setting. 
Migraine has several comorbid conditions, including epilepsy. The common 
pathophysiological mechanism of these clinical manifestations is not clear; however, the role 
of CSD and altered function of the Na+, K+ ion pump has been proposed. In the daily medical 
practice, ictal electroencephalography (EEG) recording is crucial for the differential diagnosis. 
If epileptic activity is present on EEG during ictal headache (i.e. we are dealing with an ictal 
epileptic headache), the therapeutic regime absolutely differs from the routine anti-migraine 
treatment (i.e. it requires anticonvulsants instead of triptans or analgesics). Inadequate 
management of these patients can lead to a severe condition such as ‘status epilepticus 
migrainosus’ (i.e. a nonconvulsive status epilepticus manifesting merely in headache). SM or 
persisting aura without cerebral infarction can occur in Cerebral Autosomal Dominant 
Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) patients as well 
[75-77]. Even more, drug-refractory migraine needs a worldwide consensus to have an 
adequate definition established, which should be added to the next version of the ICHD. 
A possible answer to the question ‘what is the best strategy for treating SM?’ could be to 
provide the best care (both as regards abortive and prophylactic treatment) with the tools at 
present available for migraine patients, i.e. to diminish the chance for developing SM. If SM 
occurs, we should rapidly decrease both the devastating pain and uncomfortable 
accompanying clinical signs. 
Overall, we do agree with Becker and Kryscio that our biggest challenge is to find an effective, 
safe, and tolerable acute and preventive migraine treatment in order to avoid the development 
of SM [8]. In the near future, we have a hope for new migraine prophylactic pharmacons to be 
launched, such as fully humanized antibodies targeting CGRP and CGRP receptor, which can 
bring a novel therapeutic era in migraine management. Therefore, we will have a chance to 
dramatically decrease the frequency and severity of the attacks. As an ultimate goal, we need 
to elaborate tailored and personalized migraine-specific acute treatment both at the prehospital 
and hospital levels. 
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Tables and figures 
 
 
Figure 1. Chemical structures of the referred molecules 
 
Figure 2. Chemical structures of dihydroergotamine and sumatriptan  
 
 
Table 1. Recommendations for the treatment of status migrainosus in ED setting 
 Route of 
administration 
Dosage Adverse events Contraindications Ref. 
Before taking serotonergic agents (i.e. triptans or DHE) 
DHE SC, IV 1 mg mild nausea cardiovascular diseases, 
pregnancy 
[35,58,62-
64] 
sumatriptan 
succinate 
SC  6 mg chest tightness, rash at injection site, 
generalized weakness, dizziness 
cardiovascular diseases, 
uncontrolled hypertension, 
pregnancy 
[12,35] 
After taking serotonergic agents (i.e. triptans or DHE) 
fluids 
(physiological 
saline) 
IV 500-1000 ml 
(max. 2000-
3000 ml) 
NA cardiopulmonary insufficiency [12,20] 
dexamethasone IV 10-24 mg drowsiness, dizziness, nausea, vomiting active peptic ulcer, 
uncontrolled hypertension, 
infections, immunosuppression 
[15,32,35,
40] 
magnesium sulfate IV 500-1000 mg flushing hypermagnesemia [20,35,44] 
valproates IV 500-1000 mg NA liver disease, pregnancy [12,52] 
levetiracetam IV 1000 mg NA NA [55] 
ketorolac IV 30 mg nausea, drowsiness gastrointestinal bleeding [20,35] 
acetaminophen IV 1000 mg hyperacusis, photophobia, nausea, liver 
toxicity 
hepatic dysfunction [20,35,58,
59] 
metoclopramide IV 10 mg akathisia, tardive dyskinesia, motor agitation, 
pseudoparkinsonism, drowsiness 
NA [12,20,35,
57,60] 
prochlorperazine IV 10 mg akathisia, tardive dyskinesia, motor agitation, 
pseudoparkinsonism, drowsiness 
prolonged QT intervals [12,20,35,
57,60] 
haloperidol IV 2-5 mg akathisia, tardive dyskinesia, motor agitation, 
pseudoparkinsonism, drowsiness 
NA [12,20,35,
57,60] 
Abbreviations: ED – emergency department, DHE – dihydroergotamin, IV – intravenous, NA – not available, SC – subcutaneous
  
Article highlights box 
 
 Status migrainosus, as a migraine complication, is a debilitating migraine attack 
lasting for more than 72 hours and its pharmacological management is challenging in 
the emergency setting. 
 Therapeutic options of status migrainosus depend on whether the patient has already 
received serotonergic agents (dihydroergotamine or triptans) or not for the present 
attack. 
 Drugs currently used parenterally for the treatment of status migrainosus in the 
emergency department include intravenous fluids, corticosteroids, magnesium sulfate, 
anticonvulsive drugs, non-steroidal anti-inflammatory drugs, antiemetics, and 
serotonergic agents. 
 Major adverse events (chest tightness for sumatriptan, drowsiness and nausea for 
dexamethasone, liver toxicity for acetaminophen and akathisia and tardive dyskinesia 
for antiemetics/antidopaminergic drugs) should be kept in mind.  
 In the case of rare manifestations of migraine i.e. migraine with prolonged aura, 
persistent aura without infarction, migraine aura status and ictal epileptic headache 
ketamine, anticonvulsants, antidepressants, calcium ion channel antagonists, and 
diuretics should be considered. 
 
This box summarizes key points contained in the article. 
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